ClinicalTrials.gg
CompletedNCT06169397Updated Oct 16, 2026

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

A Phase 2 interventional study of XTMAB-16 in Pulmonary Sarcoidosis, sponsored by Xentria, Inc.. Completed at 11 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Xentria, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Sarcoidosis, Pulmonary with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Sarcoidosis, Pulmonary · United States.

Enrollment
16th of 27
31 · median 37
Started
2024
with 2 others
Phase 2
12 of 33
2 open now
Registered
30th of 33
by date
Lead sponsor
2 of 33
Xentria, Inc.

Among the 33 studies in Sarcoidosis, Pulmonary with a site in United States, this one is the 16th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 in phase 2, and was the 30th registered.

Sarcoidosis, Pulmonary

67 studies on the registry are indexed under Sarcoidosis, Pulmonary; 16 are open to participants now.

Browse Sarcoidosis, Pulmonary studies →

Open to participants now

7 of the 33 studies in Sarcoidosis, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Sarcoidosis, Pulmonary studies recruiting now, 7 (58%) set no upper age limit and 1 (8%) stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Sarcoidosis, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

Read the detailed description

A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

03

Conditions studied

  • Pulmonary Sarcoidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study if the following criteria apply:

  • Completion of XTMAB-16-201 study: completion of Week 12 (Part A) or Week 24 (Part B) assessments.
  • Participants from XTMAB-16-201 Part A and Part B should be on a stable dose for at least 2 weeks prior to /Day 1 of XTMAB-16-202 (Day 1 should occur at the next scheduled dosing visit on the assigned dose frequency cohort of XTMAB 16 201 ± 2 weeks).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Evidence of treatment-related AEs requiring treatment discontinuation per XTMAB-16-201 protocol observed in XTMAB-16-201 study.
  • Evidence of treatment failure observed in XTMAB-16-201 study per protocol definition.
  • Pregnant or breastfeeding women or women who are planning to be pregnant during the course of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    XTMAB-16 Treatment

    Dose to be established in the XTMAB-16-201 Study.

    Drug: XTMAB-16

Interventions

  • DrugXTMAB-16

    XTMAB-16 infusion

06

What researchers measure

Primary outcomes

  1. Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), and Adverse Events of Special Interests (AESIs) throughout the study duration

    To evaluate the long-term safety and tolerability of XTMAB-16 in participants with pulmonary sarcoidosis with or without extra-pulmonary manifestations

    Time frame: Through study completion, an average of 4 years

Secondary outcomes

  1. Durability/maintenance of effect of XTMAB-16 as characterized by corticosteroid dosing (maintain or lower steroid dosing)

    To evaluate the durability/maintenance of effect of XTMAB-16 as characterized by corticosteroid dosing (maintain or lower steroid dosing)

    Time frame: Through study completion, an average of 4 years

  2. Durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life measured by Kings Sarcoidosis Questionnaire Lung

    To evaluate the durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life or pulmonary tests

    Time frame: Through study completion, an average of 4 years

  3. Durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life measured by Kings Sarcoidosis Questionnaire General

    To evaluate the durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life or pulmonary tests

    Time frame: Through study completion, an average of 4 years

  4. Durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life measured by Leicester Cough Questionnaire

    To evaluate the durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life or pulmonary tests

    Time frame: Through study completion, an average of 4 years

  5. Durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life measured by Steroid Toxicity Questionnaire

    To evaluate the durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life or pulmonary tests

    Time frame: Through study completion, an average of 4 years

  6. Durability/maintenance of effect of XTMAB-16 measured by Pulmonary Function Test (forced vital capacity)

    To evaluate the durability/maintenance of effect of XTMAB-16 as characterized by changes in quality of life or pulmonary tests

    Time frame: Through study completion, an average of 4 years

  7. Immunogenicity (number of participants who test positive for anti drug antibodies and/or neutralizing antibodies) in the context of long-term dosing

    To evaluate the immunogenicity of XTMAB-16 in the context of long-term dosing

    Time frame: Through study completion, an average of 4 years

  8. Long-term effect of XTAMB-16 on serum biomarkers important to cytokine pathway and granuloma formation (ACE, IL-6, sIL-2R, sTNFa, CRP, IL-1b, calcitriol) in sarcoidosis

    To evaluate the long-term effect of XTMAB-16 on serum biomarkers important to cytokine pathway and granuloma formation in sarcoidosis

    Time frame: Through study completion, an average of 4 years

07

Study locations

11 sites
  • Xentria Investigative Site
    Denver, Colorado 80206, United States
  • Xentria Investigative Site
    Chicago, Illinois 60611, United States
  • Xentria Investigative Site
    Greenville, North Carolina 27858, United States
  • Xentria Investigative Site
    Cincinnati, Ohio 45267, United States
  • Xentria Investigative Site
    Philadelphia, Pennsylvania 19140, United States
  • Xentria Investigative Site
    Prague, 140 59, Czechia
  • Xentria Investigative Site
    Bielsk Podlaski, 15-044, Poland
  • University Hospitals Coventry and Warwickshire NHS Trust
    Coventry, England CV22DX, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, England SE59RS, United Kingdom
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
    Norwich, England OX3 7LE, United Kingdom
  • NHS Tayside
    Perth, Scotland PH11NX, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2024 to primary completion in Oct 2026, 31 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Dec 13, 2023
StartActual
Mar 1, 2024
Primary completionActual
Oct 9, 2026was Nov 2026
CompletionActual
Oct 9, 2026was Nov 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Primary completion
Nov 2026→Oct 9, 2026 (actual)
Oct 16, 2026
Study completion
Nov 2026→Oct 9, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Primary completion Nov 2026→Oct 9, 2026 (now actual)
    Study completion Nov 2026→Oct 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06169397
Lead sponsor
Xentria, Inc.
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Mar 1, 2024
Primary completion
Oct 9, 2026
Completion
Oct 9, 2026
Last update
Oct 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion